SAN DIEGO, March 28, 2017 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, will
present preclinical results from recent studies describing the
latest developments of its gene delivery platform, at a poster
session at the upcoming American Association of Cancer Research
(AACR) Annual Meeting, in Washington,
D.C., on April 1- 5, 2017.
Details of the poster abstract are as follows:
- Abstract Title: Intratumoral Delivery of a P2A-linked
Bicistronic IL-12 Construct Leads to High Intratumoral Expression
and Systemic Anti-tumor Response (Abstract ID #: 1614)
- Session Title: Cytokines: The First Modern
Immunotherapies
- Date and Time: Monday, April 3,
2017 / 8:00 a.m. –
12:00 p.m. EDT
- Location: Convention Center, Halls A – C, Poster Section
26
Further details on the poster presentation will be provided in
upcoming Company communications. For more information about this
conference, please visit: www.aacr.org.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse® IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors as well as a
systemic immune response. OncoSec's lead program,
ImmunoPulse® IL-12, is currently in clinical development
for metastatic melanoma and triple-negative breast cancer. The
program's current focus is on the significant unmet medical need in
patients with melanoma who are refractory or non-responsive to
anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse®
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse®
platform. For more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "can," "may," "will," "suggest," "look
forward to," "potential," "understand," and similar references to
future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT:
Investor Relations:
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
DGI Comm
Laura Radocaj
212-825-3210
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-preclinical-data-at-the-american-association-for-cancer-research-aacr-annual-meeting-2017-300430043.html
SOURCE OncoSec Medical Incorporated